3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Prostatic Neoplasms
2
Myelodysplastic Syndromes
2
Lymphoma, Non-Hodgkin
2
Leukemia
2
Hodgkin Disease
2
Vulvar Neoplasms
1
Vulvar Diseases
1
Uterine Cervical Dysplasia
1
Small Cell Lung Carcinoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Papillomavirus Infections
1
Multiple Myeloma
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hematologic Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Carcinoma, Small Cell
1
Carcinoma in Situ
1
Interventions
pembrolizumab
20
Paclitaxel
13
Fluorouracil
13
Docetaxel
13
Radiotherapy
12
Oxaliplatin
11
Cisplatin
11
Capecitabine
8
Carboplatin
7
Leucovorin
6
Cetuximab
5
Nivolumab
4
Albumin-Bound Paclitaxel
4
atezolizumab
3
Trastuzumab
3
Ramucirumab
3
Irinotecan
3
Interleukin-2
3
Injections
3
Epirubicin
3
Drug Therapy
3
Dexamethasone
3
130-nm albumin-bound paclitaxel
3
tremelimumab
2
tisotumab vedotin
2
regorafenib
2
patritumab deruxtecan
2
oblimersen
2
nedaplatin
2
lenvatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Esophageal Neoplasms
×
Acetaminophen
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled